Multimodality Treatment of Mesenteric Desmoid Tumors Monica M. Bertagnolli, Jeffrey A. Morgan, Christopher D.M. Fletcher, Chandrajit P. Raut, Palma Dileo,

Multimodality Treatment of Mesenteric Desmoid Tumors

Monica M. Bertagnolli, Jeffrey A. Morgan, Christopher D.M. Fletcher, Chandrajit P.

Raut, Palma Dileo, Ritu R. Gill, George D. Demetri and Suzanne George

Brigham and Women’s HospitalDana-Farber Cancer Institute

Harvard Medical School

CTOS Annual MeetingLondon

November 13, 2008

Desmoid tumors Clonal proliferation of fibroblasts with an abundant collagen matrixOccur in 10-20% of patients with Familial Polyposis

mesentery 50%abdominal wall/trunk 48%extremities 2%multifocal 40%

Sporadic tumors are rare (600-1200 per year in the US)extremity 60%abdominal wall/trunk 35%mesentery 5%

Mesenteric Desmoid tumors

• Wide range of clinical behavior

• Life threatening due to impact on small bowel and mesenteric blood supply

• Surgery can be complex due to location

• Radiation may be difficult due to toxicity associated with this anatomic site

CT Characteristics

Localized Infiltrative

Methods

• Single institution retrospective review

• Consecutive series of patients with desmoid tumors of the intestinal mesentery, 2001-2005

• Patients were seen by both surgical and medical oncology

• Reviewed treatment course and outcome

Methods

• Tumor Characteristics at presentation to DFCI/BWH– Resectable vs Unresectable

• all grossly visible tumor could be removed without sacrificing small bowel function

– Progressing vs Stable– Infiltrative vs Localized

Treatment Strategy

Resectable Unresectable

Stable

Progressing

Treatment Strategy

Resectable Unresectable

Stable Surgery

Progressing

Treatment Strategy

Resectable Unresectable

Stable Surgery

Progressing Surgery

Treatment Strategy

Resectable Unresectable

Stable Surgery Observation

Progressing Surgery

Treatment Strategy

Resectable Unresectable

Stable Surgery Observation

Progressing Surgery Chemotherapy*

*1st line liposomal doxorubicin; 2nd line vinorelbine

Results: Patient Characteristics

• 52 pts– 21 FAP (age 20-50, median 31)– 31 sporadic (age 24-67, median 41)

• Prior NSAID, tamoxifen or both 60%• Prior imatinib 12%• Prior cytotoxic chemotherapy 8%

Median Followup 50 months

Results: Disease Characteristics (n=52)

• Localized disease 16 (31%) • Infiltrative disease 36 (69%)

• Progressive disease 40 (78%)• Stable disease 12 (23%)

• Resectable 36 (69%)• Unresectable 16 (31%)

Summary

Summary

Summary

Summary

Results: Extent of Surgery

Localized (n=15)Infiltrative

(n=28)

Single segment of small bowel

resected9 (60%) 9 (32%)

Multiple segments of small bowel

resected1 (7%) 15 (53%)

Positive Margins 3 (20%) 28 (100%)

Significant postop complications 16% of pts – anastomotic leak, abcess, EC fistula, postop bleed

All patients retained adequate small bowel function, no chronic TPN, no surgery associated deaths.

Results: Chemotherapy

N PR/SD* PD

Liposomal doxorubicin 10 9 1

Vinorelbine 4 3 1

Total 14 12 (94%) 2 (6%)

* by RECIST

Impact of liposomal doxorubicin in mesenteric desmoid tumor

Summary

• Multidisciplinary assessment and treatment planning is effective in patients with mesenteric desmoid tumors

• Tumor characteristics matter

• No apparent detrimental effect of surgery with regard to disease control in carefully chosen patients

• Chemotherapy can be effective in disease control

• Observation is a reasonable approach in patients with non-progressing, asymptomatic disease

Limitations

• Short followup

• Relatively small number of patients

• Variable natural history

• Mesenteric location only - unknown application to desmoids of other body sites

Thank you

Summary

Mesenteric desmoid tumors

• Localized vs diffuse disease• Incidentally discovered during 12-22% of

surgeries for FAP (Clark BrJSurg 1999, Hartley DC&R 2004)

• 2nd leading cause of disease-related mortality in patients with FAP– 13% of FAP patients with desmoids in a

series of 88 patients died within 5 years of diagnosis (Clark Br J Surg 1999)